ScholarIQanswers from OpenAlex
Institute of Cancer Research
InstitutionResearch output, impact & collaborations
Institute of Cancer Research is a institution indexed in ScholarIQ from OpenAlex.
What is known about Institute of Cancer Research?
ScholarIQrecord summary
Institute of Cancer Research is a research organisation in London, GB. OpenAlex records 27,064 works and 6,479,278 citations for it. 4,054 researchers list it as their most recent affiliation.
How many works does Institute of Cancer Research have?
ScholarIQindexed works
Institute of Cancer Research has 27,064 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Institute of Cancer Research have?
ScholarIQcitation count
Institute of Cancer Research has 6,479,278 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Institute of Cancer Research?
ScholarIQresearcher count
Institute of Cancer Research has 4,054 researchers in the ScholarIQ index.
What is the average h-index at Institute of Cancer Research?
ScholarIQavg h-index
Institute of Cancer Research has an average h-index of 76 in OpenAlex.
What is the ROR of Institute of Cancer Research?
ScholarIQror
The ROR for Institute of Cancer Research is on the source record.
What is the OpenAlex record for Institute of Cancer Research?
ScholarIQopenalex
The OpenAlex for Institute of Cancer Research is on the source record.
What is the Wikidata of Institute of Cancer Research?
ScholarIQwikidata
The Wikidata for Institute of Cancer Research is on the source record.
Who are the most-cited researchers behind Institute of Cancer Research?
ScholarIQtop researchers by citations
What are the most-cited papers on Institute of Cancer Research?
ScholarIQmost cited works
Signatures of mutational processes in human cancer
Australian Pancreatic Cancer Genome Initiative, Ludmil B. Alexandrov, ICGC PedBrain, Serena Nik‐Zainal, David C. Wedge, Samuel Aparício, Sam Behjati, Andrew V. Biankin, Graham R. Bignell, Niccolò Bolli, Åke Borg, Anne‐Lise Børresen‐Dale, Sandrine Boyault, Birgit Burkhardt, Adam P. Butler, Carlos Caldas, Helen Davies, Christine Desmedt, Roland Eils, Jórunn E. Eyfjörd, John A. Foekens, Mel Greaves, Fumie Hosoda, Barbara Hutter, Tomislav Ilicic, Sandrine Imbeaud, Marcin Imieliński, Natalie Jäger, David Jones, David R. Jones, Stian Knappskog, Marcel Kool, Sunil R. Lakhani, Carlos López-Otı́n, Sancha Martin, Nikhil C. Munshi, Hiromi Nakamura, Paul A. Northcott, Marina Pajic, Elli Papaemmanuil, Angelo Paradiso, John V. Pearson, Xosé S. Puente, Keiran Raine, Manasa Ramakrishna, Andrea L. Richardson, Julia Richter, Philip Rosenstiel, Matthias Schlesner, Ton N. Schumacher, Paul N. Span, Jon W. Teague, Yasushi Totoki, Andrew Tutt, Rafael Valdés‐Mas, Marit M. van Buuren, Laura van ‘t Veer, Anne Vincent‐Salomon, Nicola Waddell, Lucy Yates, Jessica Zucman‐Rossi, P. Andrew Futreal, Ultan McDermott, Peter Lichter, Matthew Meyerson, Sean M. Grimmond, Reiner Siebert, Elı́as Campo, Tatsuhiro Shibata, Stefan M. Pfister, Peter J. Campbell, Michael R. Stratton
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Lisa A. Carey, Charles M. Perou, Chad Livasy, Lynn G. Dressler, David P. Cowan, Kathleen Conway, Gamze Karaca, Melissa A. Troester, Chiu Kit Tse, Sharon N. Edmiston, Sandra L. Deming, Joseph Geradts, Maggie C.U. Cheang, Torsten O. Nielsen, Patricia G. Moorman, H. Shelton Earp, Robert C. Millikan
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Aron Goldhirsch, Eric P. Winer, Alan S. Coates, Richard D. Gelber, Martine Piccart, Beat Thürlimann, Hans-Jörg Senn, Kathy S. Albain, Fabrice André, Jonas Bergh, Hervé Bonnefoi, Denisse Bretel-Morales, Harold J. Burstein, Fátima Cardoso, Monica Castiglione‐Gertsch, Alan S. Coates, Marco Colleoni, Alberto Costa, Giuseppe Curigliano, Nancy E. Davidson, Angelo Di Leo, Bent Ejlertsen, John Forbes, Richard D. Gelber, Michael Gnant, Aron Goldhirsch, Pamela J. Goodwin, Paul E. Goss, Jay R. Harris, Daniel F. Hayes, Clifford A. Hudis, James N. Ingle, Jacek Jassem, Zefei Jiang, Per Karlsson, Sibylle Loibl, Monica Morrow, Moïse Namer, C. Kent Osborne, Ann H. Partridge, Frédérique Penault‐Llorca, Charles M. Perou, Martine Piccart, Kathleen I. Pritchard, Emiel J. Rutgers, Felix Sedlmayer, Semiglazov Vf, Zhi‐Ming Shao, Ian Smith, Beat Thürlimann, Masakazu Toi, Andrew Tutt, Michael Untch, Giuseppe Viale, Toru Watanabe, Nicholas Wilcken, Eric P. Winer, William C. Wood
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers
Peter C.C. Fong, David S. Boss, Timothy A. Yap, Andrew Tutt, Peijun Wu, Marja Mergui‐Roelvink, Peter G. Mortimer, Helen Swaisland, Alan Lau, Mark J. O’Connor, Alan Ashworth, James Carmichael, Stan B. Kaye, Jan H.M. Schellens, Johann S. de Bono
Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers
Karoline Kuchenbaecker, John L. Hopper, Daniel R. Barnes, Kelly‐Anne Phillips, Thea M. Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E. van Leeuwen, Roger L. Milne, Nadine Andrieu, David E. Goldgar, Mary Beth Terry, Matti A. Rookus, Douglas F. Easton, Antonis C. Antoniou, Lesley McGuffog, D. Gareth Evans, Daniel Barrowdale, Debra Frost, Julian Adlard, Kai-Ren Ong, Louise Izatt, Marc Tischkowitz, Rosalind A. Eeles, Rosemarie Davidson, Shirley Hodgson, Steve Ellis, Catherine Noguès, Christine Lasset, Dominique Stoppa‐Lyonnet, Jean‐Pierre Fricker, Laurence Faivre, Pascaline Berthet, Maartje J. Hooning, Lizet E. van der Kolk, Carolien M. Kets, Muriel A. Adank, Esther M. John, Wendy K. Chung, Irene L. Andrulis, Melissa C. Southey, Mary B. Daly, Saundra S. Buys, Ana Osório, Christoph Engel, Karin Kast, Rita K. Schmutzler, Trinidad Caldés, Anna Jakubowska, Jacques Simard, Michael Friedländer, Sue‐Anne McLachlan, Eva Macháčková, Lenka Foretová, Yen Y. Tan, Christian F. Singer, Edith Oláh, Anne‐Marie Gerdes, Brita Arver, Håkan Olsson
How much of the research on Institute of Cancer Research is open access?
ScholarIQopen access share
83%OPEN ACCESS